Retavase Articles
GE Healthcare provides $95M facility to EKR
17 March 2008
EKR licenses PDL heart drugs in deal worth up to $170M
11 February 2008
PDL share price falls 19.5% on announcement of corporate restructuring and drug divestment
10 September 2007
PDL's 4th-qtr net loss widens to $72.1M
5 March 2007
Diosynth extends deal with PDL on Retavase
12 February 2007
$250M notes placing by PDL
21 February 2005
Stock Commentary - New York
21 February 2005
PDL adjusts price for ESP Pharma
14 February 2005
Benefits of pre-hospital Retavase
8 July 2002
Pre-hospital Retavase therapy for AMI
4 September 2001
Retavase plus ReoPro improves AMI therapy
21 June 2001
ReoPro plus Retavase in MI
21 June 2000
Antiplatelet/thrombolytic combination: way forward for MI therapy?
1 September 1999
Reteplase vs alteplase in pulmonary embolism
4 August 1999
Genentech reopens patent dispute with Centocor
11 February 1999
Centocor And DuPont To End Retavase Agreement
3 December 1998
Centocor Sells Oncology Diagnostics
4 November 1998
Genentech Files Suit Against Centocor
19 March 1998
Stock Commentary New York
5 March 1998
US Approval Given For Roche's Corange Deal
26 February 1998
Centocor Completes Debenture Offering
23 February 1998
Centocor Buys Retavase Rights For $335 Million
17 February 1998
ReoPro As Adjunct To Thrombolysis; TIMI 14
20 November 1997
Roche/Corange Deal Comfirms Global Strategy
9 June 1997
GUSTO III: Activase Fends Off Retevase Challenge
20 March 1997
Boeh Mannheim Expands Biotech Role
17 March 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
BM Launches Retavase In USA
13 January 1997
First Launch Of Reteplase Follows EU/US Approvals
11 November 1996
Euro CPMP Plenary Meeting
23 September 1996
Genentech Files Suit Against Boeh Mannheim
3 June 1996
Reteplase Backed By FDA Panel
13 May 1996
New Cardiovascular Drugs Reviewed
6 May 1996
INJECT Substudy Shows Reteplase Benefit
26 February 1996
Reteplase Holds Promise For Acute MI Patients
14 August 1995
GUSTO III Study To Start In Summer
27 March 1995
Showing 1-47 of 47 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
